Vermillion Plans to Raise Up to $17.3M in Stock Offering
January 21, 2011
Vermillion Plans to Raise Up to $17.3M in Stock Offering
The company said it will use the funds to expand into international markets, fund clinical trials for its peripheral artery disease test, "pursue opportunities to diversity our product and service lines and offerings," and for general corporate purposes.
Full-text access for premium subscribers only.
Existing premium subscribers login here.
New to GenomeWeb? Register here quickly.
New to GenomeWeb? Register here quickly.
Related Stories
- Vermillion Granted US Patent Supporting PAD Biomarker
September 17, 2010 / ProteoMonitor - Vermillion Posts $344,000 in Q2 Revenues, Including First Sales of OVA1 Test
August 13, 2010 / ProteoMonitor - Vermillion Performs 3,920 OVA1 Tests in Q2, But Revenues Fall 9 Percent on Drop in Licensing Income
August 5, 2011 / ProteoMonitor - Vermillion Signs Better Revenue-Splitting Deal with Quest for OVA1, Lowers Full-Year Sales Guidance
November 12, 2010 / ProteoMonitor - Vermillion Posts 11 Percent Rise in 2012 Revenues, 8 Percent Uptick in OVA1 Sales
February 22, 2013 / ProteoMonitor